Abstract
Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.
Original language | English (US) |
---|---|
Pages (from-to) | S74-S78 |
Journal | Clinical lung cancer |
Volume | 8 |
Issue number | SUPPL. 2 |
DOIs | |
State | Published - Feb 2007 |
Keywords
- AMG-706
- Axitinib
- Cediranib
- Kinase inhibitors
- Pazopanib
- XL647
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research